Related Experiment Video
Updated: Jun 22, 2026
14:14
Adaptation of Semiautomated Circulating Tumor Cell (CTC) Assays for Clinical and Preclinical Research Applications
Published on: February 28, 2014
Circulating tumour cells in breast cancer
Alistair Ring1, Ian E Smith, Mitch Dowsett
1Academic Department of Biochemistry and the Breast Unit, Royal Marsden Hospital, London, UK.
The Lancet. Oncology
|February 6, 2004
Summary
Modern techniques can detect circulating tumor cells (CTCs) in breast cancer patients. This capability may significantly improve early diagnosis, risk assessment, relapse detection, and targeted therapies.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Circulating tumor cells (CTCs) with tumor cell characteristics are detectable in the blood of many breast cancer patients.
- Detecting and characterizing these cells could significantly impact breast cancer management.
Purpose of the Study:
- To review current techniques for detecting circulating breast cancer cells.
- To discuss the limitations of these detection methods.
- To explore the clinical relevance and future potential of CTC detection in breast cancer management.
Main Methods:
- Review of modern immunological and molecular analytical techniques for CTC detection.
- Analysis of existing clinical studies involving CTCs in breast cancer.
Main Results:
- Various techniques can detect breast cancer cells in peripheral blood.
- Limitations exist in current detection methodologies.
- Clinical studies show potential relevance for patient management.
Conclusions:
- Routine detection of circulating breast cancer cells offers promise for early diagnosis and risk stratification.
- Further research and technological advancements are needed to fully realize the potential of CTCs in breast cancer treatment and monitoring.
- Circulating tumor cell detection is a rapidly evolving field with significant implications for personalized medicine in breast cancer.
Related Concept Videos
02:17The Tumor Microenvironment
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
02:30Metastasis
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
02:40Cancer Stem Cells and Tumor Maintenance
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...